Top Manager joins Mologen's Board of Directors

Mologen Holding AG announced today that Dr. Guido G.R. Sandler will join the company as Vice Chairman of the Board of Directors. Dr. Sandler will be primarily responsible for the areas of financing, capital markets and investment management of Mologen.

The Board of Directors and the Supervisory Board have been working with Dr. Sandler for years. The Berliner Effektenbank AG, of which he was a co-founder, acted as underwriter at Mologen�s IPO and supported the company in further corporate actions.

Dr. Sandler has founded two banks and a number of investment companies. He is a member of the supervisory board of several innovative high-growth companies.

Mologen develops and utilizes new gene-based technologies and products for preventing and curing diseases. The main focus of development is on the MIDGE technology, which has been patented by Mologen. MIDGE is the ideal tool for deploying genetic information safely and efficiently as a medicine.